Document Type

Article

Publication Date

12-28-2020

Publication Title

The British journal of dermatology

Abstract

ustekinumab (UST) is a human interleukin (IL)-12/IL-23 monoclonal antibody that has been approved by the Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. Off-label use of UST has shown promising results for hidradenitis suppurativa (HS) in patients that have failed therapy with adalimumab, the only FDA approved treatment for HS.

PubMed ID

33370450

ePublication

ePub ahead of print

Available for download on Wednesday, December 29, 2021

Share

COinS